It’s up to mgt now to see how this plays out.
It plainly works in more severe DM renal failure.
Do they do another Ph2?
Do they try and licence based upon the severe disease efficacy?
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-213
-
- There are more pages in this discussion • 415 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.020(4.60%) |
Mkt cap ! $228.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 41.0¢ | $731.5K | 1.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 269178 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 14070 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |